Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Retained Earnings (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Retained Earnings for 4 consecutive years, with -$186.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 4888.42% to -$186.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$186.4 million, a 4888.42% decrease, with the full-year FY2025 number at -$178.3 million, changed N/A from a year prior.
  • Retained Earnings was -$186.4 million for Q4 2025 at Neuphoria Therapeutics, up from -$188.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$2.4 million in Q3 2024 to a low of -$188.3 million in Q3 2025.
  • A 4-year average of -$123.7 million and a median of -$153.2 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: dropped 10.25% in 2023, then tumbled 7654.67% in 2025.
  • Neuphoria Therapeutics' Retained Earnings stood at -$124.1 million in 2022, then decreased by 10.25% to -$136.9 million in 2023, then surged by 97.27% to -$3.7 million in 2024, then tumbled by 4888.42% to -$186.4 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Retained Earnings are -$186.4 million (Q4 2025), -$188.3 million (Q3 2025), and -$178.3 million (Q2 2025).